ADPT (Adaptive Biotechnologies) Forward P/E Multiple
Adaptive Biotechnologies possesses exceptional pricing power thanks to its unique clonoSEQ diagnostics. The company's forward P/E ratio reflects valuation dynamics where the 0.00 level captures current values. An AI-driven digital ecosystem makes the brand architecture indispensable for medicine. High authority among pharma behemoths confirms its innovative status, despite the anticipation of full monetization.
Analytical breakdowns for Adaptive Biotechnologies
- current price and projected stock value:
- business market valuation indicators:
- book capitalization information:
- debt and liquidity details:
Total Debt to Equity Ratio Adaptive Biotechnologies|ADPT - Long-Term Debt to Capital|Short-Term Debt to Equity Adaptive Biotechnologies|ADPT - Company Aggregate Debt|Debts to Book Capitalization Adaptive Biotech|ADPT - Long-Term Debt|Company Short-Term Debts Adaptive Biotechnologies|Quick Ratio adaptivebiotech.com
- company profitability and valuation multiples indicators:
ADPT - Company Profit|Projected Future Earnings Adaptive Biotechnologies|ADPT - P/E Multiple|Future Price to Earnings Adaptive Biotechnologies Corp|ADPT - Market Cap to Earnings and Growth Ratio|Enterprise Value to EBITDA Ratio Adaptive Biotech|ADPT - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Adaptive Biotechnologies|ADPT - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months adaptivebiotech.com|ADPT - Earnings per share growth in current year|Earnings growth forecast for next year Adaptive Biotechnologies
Summary company analytics:Adaptive Biotechnologies Corporation
The scaling of clinical diagnostics at Adaptive Biotechnologies (ADPT) amid high R&D expenditures creates a temporary gap between current expenses and future margins. An analysis of the company's forward P/E allows for a comparison of the business's market value against projected earnings, identifying points of extreme optimism or capital undervaluation, which is critical for capturing the market's real-time reaction to the company's operating leverage.
Competitors of Adaptive Biotechnologies (ADPT)
Projected Price to Earnings ARGX (argenx)|BNTX (BioNTech Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple ABVX (abivax.com)|Market Cap to Projected Earnings ADMA Corp (ADMA)|PTGX - Future Price to Earnings|immunovant.com (IMVT) - Projected Price to Earnings|Kiniksa (KNSA) - Future Price to Earnings|Projected Price to Earnings Grifols SA|Projected Price to Earnings CLDX|Forward P/E Multiple Aurinia Corp|Future Price to Earnings BioCryst (BCRX)|veratx.com - Price to Future Earnings Ratio|Forward P/E Multiple DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Projected Price to Earnings Ratio|AbCellera Bio - Forward P/E Multiple|TRML - Forward P/E Multiple|PGEN: Forward P/E Multiple|Price to Future Earnings Ratio PHAR|NKTR (Nektar Therapeutics Inc.) - Forward P/E Multiple|Forward P/E Multiple Upstream Bio, Inc.|Future Price to Earnings Zenas Biopharma, Inc. (ZBIO)|IMNM: Price to Expected Earnings Ratio|Gossamer Bio, Inc. - Projected Price to Earnings|Market Cap to Future Earnings Ratio KALV (kalvista.com)|Septerna - Forward P/E Multiple|Market Cap to Projected Earnings Pieris Pharma PVLA|SVRA (Savara Corp) - Projected Price to Earnings|RIGL (Rigel Corp) - Future Price to Earnings|ANAB (AnaptysBio, Inc.) - Forward P/E Multiple|Projected Price to Earnings Ratio astriatx.com ATXS|Projected Price to Earnings ENGN (enGene)|RAPT (RAPT Therapeutics Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple JBIO (Aerovate Therapeutics)|Aclaris Therapeutics, Inc - Future Price to Earnings|Kyverna Therapeutics - Forward P/E Multiple|Market Cap to Projected Earnings tizianalifesciences.com TLSA|Cabaletta Bio (CABA) - Future Price to Earnings|Projected Price to Earnings Ratio Ventyx Biosciences Inc. (VTYX)|Projected Price to Earnings THTX|AVTX (Avalo Therapeutics Inc) - Market Cap to Future Earnings Ratio|Forward P/E Multiple ELDN|AGEN - Projected Price to Earnings Ratio|Forward P/E Multiple CLYM (Climb Bio)|ZURA - Projected Price to Earnings|aTyr - Forward P/E Multiple|Future Price to Earnings Multiple ADAG (Adagene)|ikenaoncology.com (IMA) - Future Price to Earnings|Price to Future Earnings Ratio STTK|Future Price to Earnings Equillium Inc|Projected Price to Earnings Ratio Connect Pharma CNTB|Future Price to Earnings Immunic, Inc. (IMUX)|Future Price to Earnings ATRA (atarabio.com)|Future Price to Earnings InflaRx IFRX|x4pharma.com (XFOR) - Projected Price to Earnings Ratio|Adicet - Forward P/E Multiple|Forward Price to Earnings Multiple Celularity Inc. (CELU)|INMB: Forward P/E Multiple|BRNS - Market Cap to Projected Earnings|KZR (Kezar Life Sciences) - Forward P/E Multiple|Projected Price to Earnings Ratio sabbiotherapeutics.com SABS|Future Price to Earnings Akari Therapeutics Plc (AKTX)|Market Cap to Projected Earnings enlivex.com|Forward P/E Multiple QTTB (Q32 Bio)|Forward P/E Multiple GeoVax Corp GOVX|Edesa Biotech, Inc. - Forward P/E Multiple|IBIO (ibioinc.com) - Price to Future Earnings Ratio|carismatx.com (CARM) - Future Price to Earnings|Price to Expected Earnings Ratio XTLB (XTL Biopharmaceuticals Ltd)|Projected Price to Earnings BOLT|HCWB (HCW Biologics Inc) - Market Cap to Future Earnings Ratio|Future Price to Earnings Aptevo Therapeutics (APVO)|AIM: Price to Expected Earnings Ratio|Forward P/E Multiple ADTX (Aditxt, Inc.)|Future Price to Earnings Multiple GRI|XORTX - Forward P/E Multiple|HIND - Forward P/E Multiple|Revelation Biosciences (REVB) - Future Price to Earnings|indaptusrx.com - Future Price to Earnings Multiple|Future Price to Earnings Scinai Immunotherapeutics Ltd.|Projected Price to Earnings CalciMedica Corp (CALI)|Forward P/E Multiple AFMD|Forward P/E Multiple allakos.com (ALLK)|HOOKIPA Pharma - Projected Price to Earnings|Future Price to Earnings Multiple IGMS|iTeos Therapeutics, Inc. - Forward P/E Multiple|Market Cap to Projected Earnings Ocean Biomedical Inc OCEA|TC BioPharm (Holdings) PLC (TCBP) - Future Price to Earnings|Projected Price to Earnings Third Harmonic Bio Inc
